{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:00:13Z","timestamp":1772809213817,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,5,21]],"date-time":"2010-05-21T00:00:00Z","timestamp":1274400000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>During surgery for endometrial cancer, a pelvic lymphadenectomy with or without para-aortic lymphadenectomy is performed at least in patients with risk factors (stage I, grading 2 and\/or histological subtypes with higher risk of lymphatic spread), and is hence recommended by the International Federation of Obstetrics and Gynecology (FIGO). Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma. Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma. Tumour characteristics were analysed with respect to the surgical and pathological stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV. One hundred and thirty four (62.6%) of the patients had a histological grade 1 tumour, while 56 (26.2%) and 24 (11.2%) had a histological grade 2 or grade 3 tumour, respectively. Lymphadenectomy was performed in 151 (70.6%) patients. Only 11 (5.1%) patients showed metastatic disease in the lymph nodes. The performance of a lymphadenectomy resulted in significantly increased cause-specific and overall survival, while progression-free survival was not affected by this operative procedure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma. This increase was significant for cause-specific and overall survival, while there was a tendency only towards increased progression-free survival. Therefore, even in endometrioid adenocarcinoma, a pelvic and\/or para-aortic lymphadenectomy should be performed.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-10-224","type":"journal-article","created":{"date-parts":[[2010,5,21]],"date-time":"2010-05-21T18:26:05Z","timestamp":1274466365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?"],"prefix":"10.1186","volume":"10","author":[{"given":"Nina","family":"Bassarak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Blankenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius","family":"Dian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Bergauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Friese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Mylonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,21]]},"reference":[{"issue":"1","key":"2023_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54 (1): 8-29. 10.3322\/canjclin.54.1.8.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2023_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","volume":"8","author":"LA Gloeckler Ries","year":"2003","unstructured":"Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003, 8 (6): 541-552. 10.1634\/theoncologist.8-6-541.","journal-title":"Oncologist"},{"key":"2023_CR3","doi-asserted-by":"crossref","unstructured":"FIGO stages (announcements). Gynecol Oncol. 1989, 35: 125-127. 10.1016\/0090-8258(89)90027-9.","DOI":"10.1016\/0090-8258(89)90027-9"},{"issue":"2","key":"2023_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000069163","volume":"43","author":"J Sehouli","year":"2003","unstructured":"Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W: Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch. 2003, 43 (2): 104-110. 10.1159\/000069163.","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"issue":"1","key":"2023_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","volume":"40","author":"CP Morrow","year":"1991","unstructured":"Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991, 40 (1): 55-65. 10.1016\/0090-8258(91)90086-K.","journal-title":"Gynecol Oncol"},{"issue":"8 Suppl","key":"2023_CR6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","volume":"60","author":"WT Creasman","year":"1987","unstructured":"Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987, 60 (8 Suppl): 2035-2041.","journal-title":"Cancer"},{"issue":"1","key":"2023_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/gyno.1995.1005","volume":"56","author":"LC Kilgore","year":"1995","unstructured":"Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995, 56 (1): 29-33. 10.1006\/gyno.1995.1005.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2023_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0002-9378(97)70601-X","volume":"176","author":"JW Orr Jr","year":"1997","unstructured":"Orr JW, Holimon JL, Orr PF: Stage I corpus cancer: is teletherapy necessary?. Am J Obstet Gynecol. 1997, 176 (4): 777-788. 10.1016\/S0002-9378(97)70601-X. discussion 788-779","journal-title":"Am J Obstet Gynecol"},{"issue":"3b","key":"2023_CR9","first-page":"2073","volume":"24","author":"M Ceccaroni","year":"2004","unstructured":"Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L: Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res. 2004, 24 (3b): 2073-2078.","journal-title":"Anticancer Res"},{"issue":"4","key":"2023_CR10","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/j.ajog.2008.01.010","volume":"198","author":"NR Abu-Rustum","year":"2008","unstructured":"Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR: Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. Am J Obstet Gynecol. 2008, 198 (4): e451-455. discussion 457 e455-456","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2023_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ygyno.2005.11.032","volume":"102","author":"CV Lutman","year":"2006","unstructured":"Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT: Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006, 102 (1): 92-97. 10.1016\/j.ygyno.2005.11.032.","journal-title":"Gynecol Oncol"},{"issue":"16","key":"2023_CR12","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1200\/JCO.2005.04.144","volume":"23","author":"JM Cragun","year":"2005","unstructured":"Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005, 23 (16): 3668-3675. 10.1200\/JCO.2005.04.144.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1525-1438.2007.01020.x","volume":"18","author":"DC Smith","year":"2008","unstructured":"Smith DC, Macdonald OK, Lee CM, Gaffney DK: Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer. 2008, 18 (2): 255-261. 10.1111\/j.1525-1438.2007.01020.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"9658","key":"2023_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","volume":"373","author":"H Kitchener","year":"2009","unstructured":"Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009, 373 (9658): 125-136. 10.1016\/S0140-6736(08)61766-3.","journal-title":"Lancet"},{"issue":"6","key":"2023_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.humpath.2004.02.007","volume":"35","author":"J Prat","year":"2004","unstructured":"Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004, 35 (6): 649-662. 10.1016\/j.humpath.2004.02.007.","journal-title":"Hum Pathol"},{"issue":"16","key":"2023_CR16","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.ejca.2007.08.014","volume":"43","author":"N Shabani","year":"2007","unstructured":"Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007, 43 (16): 2434-2444. 10.1016\/j.ejca.2007.08.014.","journal-title":"Eur J Cancer"},{"issue":"7","key":"2023_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ejca.2009.01.008","volume":"45","author":"I Mylonas","year":"2009","unstructured":"Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K: Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin\/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer. 2009, 45 (7): 1304-1314. 10.1016\/j.ejca.2009.01.008.","journal-title":"Eur J Cancer"},{"key":"2023_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307\/2281868.","journal-title":"J Am Stat Assoc"},{"key":"2023_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR: Regression models and life tables. J R Stat Soc B. 1972, 34: 187-220.","journal-title":"J R Stat Soc B"},{"issue":"Suppl 1","key":"2023_CR20","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","volume":"95","author":"WT Creasman","year":"2006","unstructured":"Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S105-143. 10.1016\/S0020-7292(06)60031-3.","journal-title":"Int J Gynaecol Obstet"},{"key":"2023_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s007610050373","volume":"5","author":"G Dallenbach-Hellweg","year":"1999","unstructured":"Dallenbach-Hellweg G: Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Pr\u00e4kanzerosen. Onkologe. 1999, 5: 388-395. 10.1007\/s007610050373.","journal-title":"Onkologe"},{"issue":"1","key":"2023_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ygyno.2006.11.007","volume":"105","author":"RR Barakat","year":"2007","unstructured":"Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR: Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol. 2007, 105 (1): 150-156. 10.1016\/j.ygyno.2006.11.007.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2023_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1006\/gyno.2000.6067","volume":"80","author":"H Yabushita","year":"2001","unstructured":"Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M: Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol. 2001, 80 (2): 139-144. 10.1006\/gyno.2000.6067.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2023_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ygyno.2003.08.026","volume":"91","author":"J Gonzalez Bosquet","year":"2003","unstructured":"Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA: Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol. 2003, 91 (3): 518-525. 10.1016\/j.ygyno.2003.08.026.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2023_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/00016340802503054","volume":"87","author":"SJ Chang","year":"2008","unstructured":"Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS: Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand. 2008, 87 (12): 1361-1369. 10.1080\/00016340802503054.","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-224\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:42:23Z","timestamp":1740102143000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-224","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,21]]},"assertion":[{"value":"31 May 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"224"}}